Emmaus Life Sciences Reports Quarterly Financial Results
Prnewswire·2025-08-14 19:13
TORRANCE, Calif., Aug. 14, 2025 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQB: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial condition and results of operations as of and for the three and six months ended June 30, 2025.Highlights"We experienced a 48% decline in net revenue for the three months ended June 30, 2025 as compared to the same period in 2024 due to ongoing competition from generic L-Glutamine, partially ...